21.20.Z - Manufacture of pharmaceutical preparations and other pharmaceutical products
21.10.Z - Manufacture of basic pharmaceutical products
72.19.Z - Scientific research and development activities
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Assets | 98,7 | 94,7 | 116,8 | 23,4 |
Gross profit (loss) | 7,9 | 1,5 | 6,7 | 345,5 |
Net profit (loss) | 2,6 | 0,5 | 6,5 | 1325,7 |
Cash | 3 | 1,5 | 1,2 | -15,6 |
Net income from sale | 90,6 | 90,4 | 96,1 | 6,2 |
Liabilities and provisions for liabilities | 24,8 | 20,4 | 36 | 76,6 |
Short time liabilities | 13,1 | 10,9 | 23,5 | 115,3 |
Equity capital | 73,9 | 74,3 | 80,9 | 8,8 |
Working assets | 60,6 | 60,1 | 81,3 | 35,2 |
Operating profit (EBIT) | 14,8 | 4,9 | 14 | 187,9 |
% | % | % | p.p. | |
Equity capital to total assets | 74,9 | 78,5 | 69,2 | -9,3 |
Gross profit margin | 8,7 | 1,7 | 6,9 | 5,2 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 53 | 44 | 89 | 45 |
Current financial liquidity indicator | 3.176372766494751 | 3.563911199569702 | 2.8159639835357666 | -0,8 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane